U.S. markets close in 5 hours 27 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.45+0.01 (+0.07%)
As of 10:32AM EST. Market open.

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
http://www.cerevel.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees100

Key Executives

NameTitlePayExercisedYear Born
Dr. N. Anthony Coles Jr.Pres, CEO & Exec. Chairman921.37kN/A1960
Dr. John J. Renger Ph.D.Chief Scientific Officer639.69kN/A1969
Dr. Ramiro SanchezChief Medical Officer1.2MN/A1961
Ms. Kathy Y. YiChief Financial OfficerN/AN/A1972
Mr. Mark BodenraderVP of Fin. & Chief Accounting OfficerN/AN/A1972
Mr. Bryan K. PhillipsChief Legal OfficerN/AN/A1971
Mr. Kenneth A. DiPietroChief HR OfficerN/AN/A1959
Ms. Orly MishanVP & Chief Bus. OfficerN/AN/A1972
Ms. Kathleen TregoningChief Corp. Affairs OfficerN/AN/A1971
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cerevel Therapeutics Holdings, Inc. operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III program for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cerevel Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.